Navicular Drug Receives FDA Approval

Tildren is approved to control clinical signs associated with navicular syndrome in horses.
Share
Favorite
Close

No account yet? Register

ADVERTISEMENT

Tildren (tiludronate disodium) has received U.S. Food and Drug Administration approval and is now available to U.S. equine veterinarians to help manage navicular syndrome.

With the recent FDA approval, Ceva Animal Health began selling Tildren in the United States in early December. Approved to control clinical signs associated with navicular syndrome in horses, Tildren is available for veterinarians to purchase through national distribution channels.

Tildren is designed to regulate osteoclasts in areas of excessive activity. In navicular syndrome, excessive mechanical stress results in bone resorption outpacing bone formation. Tildren works at areas of active bone resorption, restoring balance to the process of bone remodeling.

Tildren has been used worldwide for more than 12 years with more than 250,000 doses administered. Some U.S. veterinarians are already familiar with the product due to its use in international markets

Create a free account with TheHorse.com to view this content.

TheHorse.com is home to thousands of free articles about horse health care. In order to access some of our exclusive free content, you must be signed into TheHorse.com.

Start your free account today!

Already have an account?
and continue reading.

Share

Written by:

Related Articles

Stay on top of the most recent Horse Health news with

FREE weekly newsletters from TheHorse.com

Sponsored Content

Weekly Poll

sponsored by:

How much time do you usually spend grooming your horse?
433 votes · 433 answers

Readers’ Most Popular

Sign In

Don’t have an account? Register for a FREE account here.

Need to update your account?

You need to be logged in to fill out this form

Create a free account with TheHorse.com!